Recombinant proteins used in biomedical research, diagnostics and different therapies are
mostly produced in Chinese hamster ovary cells in the pharmaceutical industry. These …

Over the last years, the biopharmaceutical industry has significantly turned its biologics
production towards mammalian cell expression systems. The presence of glycosylation …

Purpose To evaluate features and outcomes of eyes with retinal vasculitis and intraocular
inflammation (IOI) after intravitreal injection (IVI) of brolucizumab 6 mg/0.05 ml for treatment …

The manufacturing of recombinant protein is traditionally undertaken in mammalian cell
culture. Today, speed, cost and safety are the primary considerations for process …

Minority US populations are underrepresented in cancer clinical trials. This review appraises
the impact of the disparity in clinical trial participation by minority patients in the current era …

Background: Evolocumab and other anti-PCSK9 antibodies reduced adverse cardiovascular
outcomes in clinical trials of high-risk patients over< 3 years median treatment duration …

The global pharmaceutical market has recently shifted its focus from small molecule drugs to
peptide, protein, and nucleic acid drugs, which now comprise a majority of the top-selling …

Peptides and proteins are preponderantly emerging in the drug market, as shown by the
increasing number of biopharmaceutics already approved or under development …

The subcutaneous route of administration has provided convenient and non-inferior delivery
of therapeutic proteins compared to intravenous infusion, but there is potential for enhanced …

Nowadays, nanotechnology-based modulation of the immune system is presented as a
cutting-edge strategy, which may lead to significant improvements in the treatment of severe …